Reaction

Chronic Gastritis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,207 reports · 68 co-occurring drugs

As of the last recalculation, Chronic Gastritis appears in 2,207 FAERS reports alongside 68 co-occurring drug terms. The strongest observed disproportionality signal is OLMESARTAN MEDOXOMIL (PRR 19.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Olmesartan Medoxomil	73	19.8	19.8
Indapamide	28	14.9	14.9
Torsemide	44	12.8	12.8
Methimazole	9	10.9	10.9
Doxepin Hydrochloride	14	10.5	10.5
Doxepin	11	10.3	10.3
Indomethacin	14	10.0	10.0
Candesartan	37	9.9	9.9
Ipilimumab	44	9.8	9.8
Basiliximab	12	9.7	9.7
Tenofovir Disoproxil Fumarate Tablets	8	8.8	8.8
Valsartan Oral	49	8.7	8.7
Propofol	33	8.6	8.6
Telmisartan	16	8.5	8.5
Pitavastatin Calcium	9	8.3	8.3
Isosorbide Dinitrate	17	8.3	8.3
Metoprolol Succinate Er Tablets	53	8.2	8.2
Diclofenac	69	7.8	7.8
Valganciclovir Hydrochloride Powder,	10	7.8	7.8
Posaconazole Delayed-Release	9	7.8	7.8
Candesartan Cilexetil	21	7.6	7.6
Febuxostat Tablets 40 Mg	8	7.4	7.4
Febuxostat Tablets 80 Mg	8	7.4	7.4
Esomeprazole	48	7.4	7.4
Sucralfate Oral	11	7.3	7.3
Sucralfate Oral Suspension	11	7.3	7.3
Diclofenac Sodium 1%	27	7.2	7.2
Diclofenac Sodium Topical	27	7.2	7.2
Diclofenac Sodium Topical Gel, 1%	27	7.2	7.2
Nebivolol	12	7.1	7.1
Clarithromycin	25	6.9	6.9
Daspone	7	6.8	6.8
Dapsone Gel, 5%	7	6.8	6.8
Ticagrelor	22	6.6	6.6
Valganciclovir	13	6.5	6.5
Valganciclovir Hydrochloride	13	6.5	6.5
Triamcinolone Acetonide Ointment Usp, 0.05%	16	6.5	6.5
Entecavir	8	6.5	6.5
Metoprolol Succinate	57	6.3	6.3
Gefitinib	6	6.3	6.3
Dapsone	7	6.2	6.2
Baricitinib	6	5.9	5.9
Suvorexant	8	5.8	5.8
Sitagliptin And Metformin Hydrochloride	12	5.3	5.3
Insulin Degludec	13	5.2	5.3
Canakinumab	6	5.2	5.2
Posaconazole	9	5.2	5.2
Febuxostat	9	5.1	5.1
Nivolumab	50	5.0	5.0
Triamcinolone Acetonide	16	4.9	4.9
Pembrolizumab	52	4.7	4.8
Rotigotine	7	4.6	4.6
Iohexol	4	4.6	4.6
Ado-Trastuzumab Emtansine	4	4.5	4.5
Dapagliflozin	14	4.2	4.2
Tenofovir Disoproxil Fumarate	14	4.0	4.0
Ocrelizumab	26	4.0	4.0
Vedolizumab	33	3.7	3.7
Rifaximin	8	3.6	3.6
Fremanezumab-Vfrm	4	3.3	3.3
Golimumab	29	3.2	3.2
Atezolizumab	13	3.2	3.2
Palivizumab	5	3.1	3.1
Axitinib	5	2.4	2.4
Tapentadol Hydrochloride	7	2.0	2.0
Osimertinib	6	1.8	1.8
Cinacalcet Hydrochloride	6	1.2	1.2
Galcanezumab-Gnlm	4	1.2	1.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.